Rising prevalence of conjunctivitis is propelling the growth of the viral conjunctivitis drugs market
The
most commonly used viral conjunctivitis drugs are antibiotics. These drugs,
including amikacin, doxycycline, and gentamycin are effective in the treatment
of this condition. Doxycycline can cause
nausea, vomiting, diarrhea, dizziness, hives, and even bleeding, and these
effects can be severe if they persist for a long time. Gentamycin, on the other
hand, causes diarrhea and produces thin discharge from the nose.
The
growing prevalence of conjunctivitis or pink eye is a key factor fueling the
growth of the viral conjunctivitis drugs market. Conjunctivitis drugs are used
to treat inflammation or swelling of the conjunctiva. A rise in hygiene and
awareness coupled with the increasing healthcare expenditure is also propelling
the growth of viral conjunctivitis drugs. According to the World Health
Organization, global spending on health continues to rise. It was US$ 7.8
trillion in 2017 or about 10% of GDP and $1,080 per capita – up from US$ 7.6
trillion in 2016. The increasing geriatric population which is increasing the
prevalence rate of this infection is further anticipated to augment the growth
of the viral
conjunctivitis drugs market.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the high prevalence of viral conjunctivitis in the
region. According to the National Center for Biotechnology Information, it is
estimated that acute conjunctivitis affects 6 million people annually in the
United States.2 The cost of treating bacterial conjunctivitis alone was
estimated to be $377 million to $857 million per year.
Key Developments:
1. In July 2017, Lupin Ltd has
launched in the US market its generic version of Moxifloxacin Hydrochloride
Ophthalmic solution used for treating bacterial conjunctivitis.
2. In December 2020, Ocular
Therapeutix, Inc. a biopharmaceutical company focused on the formulation,
development, and commercialization of therapies for diseases and conditions of
the eye announced the submission of the supplemental New Drug Application
(sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA®
(dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use
3. In March 2020, Eyevance announced
the launch of Zerviate™ (cetirizine ophthalmic solution) 0.24% for the
treatment of ocular itching associated with allergic conjunctivitis in patients
2 years of age and older.
4. In March 2019, Alembic
Pharmaceuticals announced that it has received approval from the United States
Food and Drug Administration for sales of a generic version of Mylan’s Optivar
eye-drops
Comments
Post a Comment